… transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the … seen firsthand the transformative potential of ProQR’s Axiomer RNA editing platform. I am excited to join the …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced … webcast will be available for approximately 30 days. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… transformative RNA therapies based on its proprietary Axiomer® RNA editing technology platform, today announced the … has served on ProQR’s Supervisory Board since 2014. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued … transformative RNA therapies based on its proprietary Axiomer ® RNA editing technology platform, today reported its …
… trial in 2022. RNA base-editing platform technologies – Axiomer ® and Trident ® ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and shown … will develop selected genetic eye disease targets with Axiomer ® , and will provide further guidance on this in H2 …
… with Lilly highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial … 18, 2021 to highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & … the partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of …
… we are excited by the potential of our next-generation Axiomer RNA editing technology. In addition to using this … this trial in 2022. ProQR has been further optimizing the Axiomer ® Editing Oligonucleotide (EON) designs and will develop selected genetic eye disease targets with Axiomer ® . The Company anticipates providing further …
… pigmentosa ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across … pigmentosa. ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and … The Company will present further non-clinical data for Axiomer and announce its internal development targets in H2 …